Denali Therapeutics (DNLI) director receives RSU and stock option awards

Rhea-AI Filing Summary

Denali Therapeutics director Steve E. Krognes reported equity awards and updated holdings. He received 6,408 shares of common stock in the form of Restricted Stock Units, which will vest 100% on the earlier of the one-year anniversary of the grant date or the day before Denali’s next annual stockholder meeting. He was also granted stock options for 19,226 shares at an exercise price of $19.66 per share, with the same vesting schedule and an expiration date in 2036. Following these grants, he holds 38,202 shares directly and 781,797 shares indirectly through The Steve Edward Krognes Revocable Trust, where he serves as trustee.

Insights

Equity compensation analyst

Director receives routine RSU and stock option grants, no open-market trades.

Denali Therapeutics awarded director Steve E. Krognes 6,408 Restricted Stock Units and options for 19,226 shares at $19.66 per share. These are compensation-related grants, not market purchases or sales, and reflect standard board equity incentives.

Both the RSUs and options vest fully on the earlier of the one-year anniversary of the June 3, 2026 grant date or the day before the next annual stockholder meeting. Krognes’s reported holdings total 38,202 shares directly plus 781,797 shares indirectly via a revocable trust, indicating a substantial ongoing stake.

The filing shows no open-market buying or selling activity, and derivativeSummary lists no remaining option positions beyond this new grant. Future company filings may update vesting or additional awards, but this report alone mainly documents routine compensation and ownership levels.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Krognes Steve E.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	19,226	$0.00	--
Grant/Award	Common Stock	6,408	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 19,226 shares (Direct, null); Common Stock — 38,202 shares (Direct, null); Common Stock — 781,797 shares (Indirect, See footnote)

Footnotes (1)

1. Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Includes 6,408 unvested RSUs. The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

Key Figures

RSU grant: 6,408 RSUs Option grant size: 19,226 options Option exercise price: $19.66 per share +4 more

7 metrics

RSU grant 6,408 RSUs Common stock RSUs granted on June 3, 2026

Option grant size 19,226 options Stock options for common stock granted on June 3, 2026

Option exercise price $19.66 per share Exercise price for 19,226 stock options

Option expiration June 3, 2036 Expiration date of stock options

Direct holdings after grant 38,202 shares Total direct common stock holdings following transactions

Indirect trust holdings 781,797 shares Shares held by The Steve Edward Krognes Revocable Trust

Unvested RSUs included 6,408 RSUs Unvested portion included in direct holdings

Key Terms

Restricted Stock Unit ("RSU"), Revocable Trust, Stock Option (right to buy), vest

4 terms

Restricted Stock Unit ("RSU") financial

"Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share"

Revocable Trust financial

"The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016"

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

Stock Option (right to buy) financial

"security_title": "Stock Option (right to buy)""

vest financial

"100% of the RSUs shall vest upon the earlier of (i) the one year anniversary"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krognes Steve E.

(Last) (First) (Middle)

C/O DENALI THERAPEUTICS INC.

161 OYSTER POINT BLVD.

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Denali Therapeutics Inc. [ DNLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/03/2026		A		6,408(1)	A	$0	38,202(2)	D
Common Stock								781,797	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$19.66	06/03/2026		A		19,226		(4)	06/03/2036	Common Stock	19,226	$0	19,226	D

Explanation of Responses:

1. Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

2. Includes 6,408 unvested RSUs.

3. The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.

4. 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

Remarks:

	/s/ Tyler Nielsen, by power of attorney	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Denali Therapeutics (DNLI) grant to Steve E. Krognes in this Form 4?

Denali Therapeutics granted Steve E. Krognes 6,408 Restricted Stock Units and stock options for 19,226 shares at an exercise price of $19.66 per share, all dated June 3, 2026 as compensation, not open-market transactions.

How do the new RSUs for Steve E. Krognes at Denali Therapeutics (DNLI) vest?

All 6,408 Restricted Stock Units vest 100% on the earlier of the one-year anniversary of the grant date or the day before Denali Therapeutics’ next annual stockholder meeting, aligning director compensation with short- to medium-term company performance and governance cycles.

What are the terms of Steve E. Krognes’s new stock options at Denali Therapeutics (DNLI)?

Krognes received stock options for 19,226 shares of Denali Therapeutics common stock at an exercise price of $19.66 per share. These options vest fully on the same schedule as the RSUs and expire on June 3, 2036, providing long-dated upside exposure.

How many Denali Therapeutics (DNLI) shares does Steve E. Krognes hold after these transactions?

After the reported grants, Krognes holds 38,202 shares of Denali Therapeutics common stock directly, including 6,408 unvested RSUs, and 781,797 shares indirectly through The Steve Edward Krognes Revocable Trust, where he serves as trustee and holds record ownership.

Were there any open-market buys or sells by Steve E. Krognes in this Denali Therapeutics (DNLI) Form 4?

No open-market purchases or sales are reported. The Form 4 reflects compensation-related acquisitions only: 6,408 RSUs and 19,226 stock options granted at $19.66 per share, plus an update to indirect holdings through a revocable trust.

What is the role of The Steve Edward Krognes Revocable Trust in Denali Therapeutics (DNLI) share ownership?

The trust holds 781,797 Denali Therapeutics shares of record, with Steve E. Krognes serving as trustee. This means a large portion of his reported beneficial ownership is held indirectly via the revocable trust rather than directly in his personal name.